In a recent announcement, Charles River Laboratories International, Inc. has entered into a collaboration agreement with Pluristyx Inc. a renowned provider of tools, technologies, and services for cell therapy development. This collaboration expands Charles River’s access to a wide range of highly characterized and unique stem cell lines, including embryonic stem cells (ES) and induced pluripotent stem cells (iPSCs). This article will outline the key facts and developments related to this partnership, as well as highlight a significant manufacturing milestone achieved by Charles River in its cell therapy collaboration with Vertex Pharmaceuticals.
Expanding Stem Cell Portfolio
Charles River Laboratories International, Inc. a global contract research organization (CRO), has partnered with Pluristyx Inc. a leader in cell therapy tools and technologies. Through this collaboration, Charles River gains broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem cells (ES) and induced pluripotent stem cells (iPSCs). These stem cell lines will serve as essential research tools to support the development of cell therapies. The partnership highlights Charles River’s commitment to advancing the field of regenerative medicine by bolstering its stem cell portfolio.
Streamlining Adeno-Associated Viral Vector Manufacturing
In addition to its collaboration with Pluristyx, Charles River has further expanded its offerings in the gene therapy space. The company recently launched its off-the-shelf Rep/Cap plasmid products, aimed at streamlining adeno-associated virus (AAV)-based gene therapy programs. This comprehensive range of contract development and manufacturing organization (CDMO) products includes lentiviral packaging and AAV Helper plasmid offerings. Charles River’s Rep/Cap plasmid supplements enhance its capabilities in AAV-based gene therapy, positioning the company as a key player in this rapidly evolving field.
Milestone Achievement in Cell Therapy Manufacturing Collaboration
Charles River and Vertex Pharmaceuticals have made a significant stride in their strategic collaboration to manufacture CASGEVY (exagamglogene autotemcel exa-cel), a cell therapy approved in certain countries for eligible patients. Charles River’s Memphis center of excellence recently achieved back-to-back audits from both the U.S. Food and Drug Administration (FDA) and the Health Products Regulatory Authority, demonstrating the center’s adherence to regulatory standards for cell therapy manufacturing. This accomplishment reflects the successful progress made by Charles River and Vertex Pharmaceuticals in their ongoing partnership to advance cell therapy development.
Conclusion:
Charles River Laboratories International, Inc.’s collaboration with Pluristyx Inc. has bolstered its stem cell portfolio, providing access to highly characterized and unique stem cell lines. Additionally, Charles River’s offerings in gene therapy manufacturing have been further streamlined through the launch of Rep/Cap plasmids. The company’s cell therapy manufacturing collaboration with Vertex Pharmaceuticals has also reached a significant milestone, with its Memphis center of excellence passing rigorous regulatory audits. These achievements underscore Charles River’s commitment to advancing the field of regenerative medicine and its position as a leader in the cell therapy industry.
Comments